NCT01831427 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2013

Primary Completion Date

January 5, 2015

Study Completion Date

February 6, 2015

Conditions

Ulcerative Colitis

Interventions

DRUG

Andecaliximab

Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

DRUG

Placebo to match Andecaliximab

Placebo to match andecaliximab administered by IV infusion

Trial Locations (16)

1083

Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest

2025

Republican Clinical Hospital, Chisinau

3000

UZ Leuven, Leuven

4031

Clinical Pharma Center of Kenezy Gyula Korhaz Rendelointezet, Debrecen

8230

Drug Research Centre, Balatonfüred

27710

Duke University Medical Center, Durham

45255

Community Research, Cincinnati

48047

Clinical Research Institute of Michigan, Chesterfield Township, MI 48047

64012

Ehrhardt Clinical Research, LLC, Belton

71201

Delta Research Partners LLC, Monroe

20889-5600

Walter Reed National Military Medical Center, Bethesda

V6Z 2K5

GIRI, Vancouver

N6A 5A5

LHSC University Campus, London

1105 AZ

Academic Medical Center, Amsterdam

6229 HX

Academisch Ziekenhuis Maastricht, Maastricht

050159

"Institute of Pulmonology Marius Nasta", Bucharest